Supreme Court Divided Over Roundup Weedkiller Case: What's at Stake for Millions
The Supreme Court heard arguments in a case that could determine whether thousands of Americans can sue Bayer-Monsanto over claims its Roundup weedkiller causes cancer. The justices appeared genuinely divided, and the outcome could reshape pesticide regulation, corporate liability, and even the 2026 midterm elections.
Picture this: for more than 20 years, John Durnell was the "spray guy" for his neighborhood association in a historic St. Louis community. He'd walk the parks, spraying Roundup to keep the weeds down. It was a community service, something he did to help his neighbors.
Then came the diagnosis: non-Hodgkin lymphoma, an aggressive form of cancer.
Durnell believed the weedkiller he'd trusted for decades was responsible. In 2019, he sued Monsanto, the company that invented Roundup and was later acquired by German pharmaceutical and agricultural giant Bayer in a $63 billion deal.
A Missouri jury agreed with him. In 2023, they awarded Durnell $1.25 million in damages, finding that Monsanto had failed to warn him about the potential cancer risks of its product.
That verdict, one among tens of thousands of similar cases — is now at the center of a Supreme Court battle that could fundamentally reshape Americans' ability to hold pesticide companies accountable.
What the Supreme Court Is Actually Deciding
This isn't a case about whether Roundup causes cancer. (Though that question hovers over everything.) The justices are wrestling with a narrower, but enormously consequential, legal question:
Does federal pesticide law block people from suing under state laws that require companies to warn consumers about potential dangers?
The law at issue is the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) , originally passed in 1947 and amended several times since. FIFRA requires pesticide manufacturers to register their products with the Environmental Protection Agency and submit proposed labeling for approval.
Crucially, FIFRA contains a provision saying states cannot impose labeling requirements "in addition to or different from" those set by the EPA.
Bayer's argument, delivered before the Court by attorney Paul Clement, goes like this: The EPA has repeatedly reviewed glyphosate (the active ingredient in Roundup) and has consistently determined it does not cause cancer in humans when used as directed. The EPA therefore requires no cancer warning on Roundup's label. If a Missouri jury forces the company to pay damages for not including a warning the EPA specifically rejected, that jury is effectively imposing a labeling requirement "different from" what federal law demands, and that's preempted.
"A Missouri jury imposed a cancer-warning requirement that the EPA does not require. That additional requirement is preempted," Clement told the justices.
Durnell's legal team, led by attorney Ashley Keller, countered with a different reading of the same law. Yes, FIFRA prohibits states from imposing additional labeling rules. But it also separately makes it unlawful to sell pesticides that are "misbranded", meaning their labels lack adequate warnings to protect health. Keller argued that the EPA's approval of a label doesn't immunize a manufacturer from liability if that label is misleading or inadequate. EPA registration is not a "get out of jail free" card.
"Monsanto now asks you for the opposite holding, that Roundup cannot be misbranded as a matter of law because EPA found for the first time 50 years ago as a matter of fact that it is safe, based on information Monsanto submitted," Keller said.
The Justices Appeared Genuinely Divided
Here's where it gets interesting, and unpredictable. The oral arguments didn't break neatly along the Court's familiar 6-3 conservative-liberal split.
Justice Brett Kavanaugh (a Trump appointee) seemed firmly in Bayer's corner. He emphasized that the whole point of FIFRA is uniformity, one national standard for pesticide labels. If every state can effectively impose different warning requirements through lawsuits, that uniformity collapses.
Justice Neil Gorsuch (another Trump appointee) pressed Bayer's lawyer hard from a different angle. He wanted to know: if the EPA can bring criminal and civil penalties against a company for misbranding despite having registered the product, why can't state courts do the same thing through tort lawsuits?
Chief Justice John Roberts articulated what might be the most important practical concern. What happens if new scientific evidence emerges suggesting a pesticide is dangerous, but the EPA takes years to update its assessment? Are states supposed to just sit on their hands while people keep getting exposed?
"If it turns out that they were right, it might have been good if they had an opportunity to do something to call this danger to the attention of the people while the federal government was going through its process," Roberts observed.
Justice Elena Kagan seemed worried about the "patchwork" problem Bayer identified, different rules in different states, but she also asked pointed questions suggesting she wasn't fully convinced by Bayer's broad preemption argument.
The honest takeaway: nobody knows how this comes out. The Court is split, and the final decision could hinge on how the justices ultimately frame the question.
The Science Battle That Won't Go Away
For all the legal technicality, you can't understand this case without grasping the fierce scientific debate in the background.
In 2015, the International Agency for Research on Cancer (IARC) — part of the World Health Organization, classified glyphosate as "probably carcinogenic to humans" based on limited evidence in humans and sufficient evidence in animal studies.
The EPA, however, has consistently reached the opposite conclusion. After its own comprehensive review, the agency determined glyphosate is "not likely to be carcinogenic to humans" when used according to label directions.
So who's right? That depends on whom you ask, and which studies you trust. Bayer points to the EPA's findings and says it's simply following what federal regulators require. Plaintiffs point to IARC and argue that the company should have warned users about what the WHO's cancer research arm found.
This scientific uncertainty is central to why Bayer wants the legal question resolved at the Supreme Court. As long as juries can hear competing expert testimony about whether glyphosate causes cancer, some plaintiffs will win, sometimes with staggering damages awards.
The Political Drama: MAHA vs. Trump
Here's a twist that makes this case unusually politically charged: the Trump administration sided with Bayer — filing a brief arguing that FIFRA preempts the state lawsuits.
This has infuriated the Make America Healthy Again (MAHA) movement — a coalition of health-conscious voters, many of whom supported Trump, who want to rein in pesticide use and "make America healthy." MAHA's most prominent champion is Health and Human Services Secretary Robert F. Kennedy Jr. , who has spent years publicly warning about glyphosate's dangers.
Activists rallied outside the Supreme Court during oral arguments, holding signs and chanting, a rare sight for a case about pesticide labeling.
The tension is real. In February 2026, Trump signed an executive order declaring glyphosate "critical to the national defense" and granting limited legal immunity to manufacturers complying with federal directives.MAHA supporters felt betrayed. With midterms approaching, some have threatened to withhold support from Republican candidates they see as protecting Big Agriculture at the expense of public health.
The Financial Picture: Billions at Stake
Let's talk numbers, because they're staggering.
Bayer acquired Monsanto in 2018 for $63 billion — and the Roundup litigation has been an anchor on the company ever since. Since that acquisition, Bayer has already paid roughly $10 billion to settle existing Roundup claims.
In February 2026, the company proposed a $7.25 billion class-action settlement designed to resolve both current and future claims alleging non-Hodgkin lymphoma from Roundup exposure.A Missouri court granted preliminary approval to that settlement in March 2026.
Bayer has also set aside approximately €11.8 billion (around $13 billion) in total litigation reserves for glyphosate-related matters.
The company faces more than 100,000 pending claims — and has warned it might need to pull glyphosate from the U.S. agricultural market entirely if the litigation isn't resolved in its favor.
What Happens Next, and What It Means for You
The Supreme Court will issue its decision by late June or early July 2026. Here's what to watch for:
If Bayer wins: Thousands of failure-to-warn lawsuits would likely be dismissed. The legal theory that juries can impose liability for not including cancer warnings the EPA rejected would be substantially foreclosed. Bayer would breathe a massive sigh of relief, and Roundup would likely remain on agricultural shelves.
If Durnell wins: The lawsuits continue. Bayer would face ongoing litigation exposure in state courts across the country, with the prospect of more multibillion-dollar verdicts. The company has made clear it would then need to "consider its options", potentially including pulling glyphosate from the U.S. market.
For farmers: Glyphosate is integral to modern American agriculture, used with genetically modified seeds that resist the herbicide's effects. Farmers worry that if glyphosate becomes unavailable or prohibitively expensive to insure, it could disrupt crop production and increase costs.
For consumers: Bayer has already removed glyphosate from Roundup sold in the U.S. residential lawn and garden market, replacing it with different active ingredients. Agricultural-use Roundup still contains glyphosate.
Beyond the legal doctrine and the corporate balance sheets, this case raises a question that resonates far beyond pesticides: Who gets to decide what's safe enough? Is it federal regulatory agencies, applying their scientific expertise in a deliberate, some would say slow, process? Or do state courts and juries have a role to play in holding companies accountable when new evidence of harm emerges?
The Supreme Court's answer will shape not just the fate of Roundup litigation, but the broader landscape of product liability law in America. It will determine whether the EPA's stamp of approval is a shield against lawsuits, or just one piece of a larger puzzle that includes state consumer protection laws and the judgment of ordinary citizens serving on juries.
John Durnell, the "spray guy" from St. Louis, probably never imagined his case would reach the highest court in the land. But here we are, and millions of people have a stake in the outcome.